Wang Yufeng, Drum David L, Sun Ruochuan, Zhang Yida, Yu Ling, Jia Lin, Isakoff Steven J, Kehlmann Allison M, Dal Ali Emre, Dotti Gianpietro, Zheng Hui, Ferrone Cristina R, Taghian Alphonse G, DeLeo Albert B, Zhang Hanyu, Jounaidi Youssef, Fan Song, Huang Peigen, Wang Cheng, Yang Jibing, Boland Genevieve M, Sadreyev Ruslan I, Wong LaiPing, Ferrone Soldano, Wang Xinhui
Res Sq. 2023 Feb 21:rs.3.rs-2595410. doi: 10.21203/rs.3.rs-2595410/v1.
The poor efficacy of chimeric antigen receptor T-cell therapy (CAR T) for solid tumor is due to insufficient CAR T cell tumor infiltration, in vivo expansion, persistence, and effector function, as well as exhaustion, intrinsic target antigen heterogeneity or antigen loss of target cancer cells, and immunosuppressive tumor microenvironment (TME). Here we describe a broadly applicable nongenetic approach that simultaneously addresses the multiple challenges of CAR T as a therapy for solid tumors. The approach massively reprograms CAR T cells by exposing them to stressed target cancer cells which have been exposed to the cell stress inducer disulfiram (DSF) and copper (Cu)(DSF/Cu) plus ionizing irradiation (IR). The reprogrammed CAR T cells acquired early memory-like characteristics, potent cytotoxicity, enhanced in vivo expansion, persistence, and decreased exhaustion. Tumors stressed by DSF/Cu and IR also reprogrammed and reversed immunosuppressive TME in humanized mice. The reprogrammed CAR T cells, derived from peripheral blood mononuclear cells (PBMC) of healthy or metastatic breast cancer patients, induced robust, sustained memory and curative anti-solid tumor responses in multiple xenograft mouse models, establishing proof of concept for empowering CAR T by stressing tumor as a novel therapy for solid tumor.
嵌合抗原受体T细胞疗法(CAR T)对实体瘤疗效不佳,原因在于CAR T细胞的肿瘤浸润不足、体内扩增能力有限、持久性差、效应功能欠佳,以及耗竭、内在靶抗原异质性或靶癌细胞的抗原丢失,还有免疫抑制性肿瘤微环境(TME)。在此,我们描述了一种广泛适用的非基因方法,该方法同时解决了CAR T作为实体瘤治疗方法所面临的多重挑战。该方法通过将CAR T细胞暴露于已接触细胞应激诱导剂双硫仑(DSF)和铜(Cu)(DSF/Cu)并接受电离辐射(IR)的应激靶癌细胞,对CAR T细胞进行大规模重编程。重编程后的CAR T细胞获得了早期记忆样特征、强大的细胞毒性、增强的体内扩增能力、持久性,并减少了耗竭。在人源化小鼠中,受DSF/Cu和IR应激的肿瘤也发生了重编程并逆转了免疫抑制性TME。源自健康或转移性乳腺癌患者外周血单核细胞(PBMC)的重编程CAR T细胞,在多个异种移植小鼠模型中诱导了强大、持久的记忆性和治愈性抗实体瘤反应,为通过应激肿瘤增强CAR T作为实体瘤的新型治疗方法建立了概念验证。